Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Metopirone
metyrapone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Metyrapone | EXPERIMENTAL | Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved. |
| Name | Type | Description |
|---|---|---|
| metyrapone | DRUG | Single arm study |
Inclusion Criteria: 1\. Patients with endogenous Cushing's syndrome: * Cushing disease patients with persistent or recurrent disease (after pituitary surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to defer surgery; * Patients with ectopic ACTH syndrome (either occ...
Metyrapone is a small molecule being developed by Perrigo Company plc for the treatment of endogenous Cushing's Syndrome. It is designed to lower cortisol production in patients with this endocrine disorder. The drug is currently in Phase 3 clinical development and is not yet approved.
Metyrapone targets CYP11B1, an enzyme involved in cortisol synthesis. It acts as an inhibitor of this target, which is the basis for its use in Cushing's Syndrome, a condition characterized by excess cortisol. By inhibiting CYP11B1, metyrapone aims to reduce cortisol production.
Metyrapone is being developed by Perrigo Company plc, which trades under the ticker PRGO. The company is advancing the drug as a treatment for endogenous Cushing's Syndrome in Phase 3 clinical development.
Metyrapone is in Phase 3 clinical development for Cushing's Syndrome. It is an investigational small molecule and has not been approved by the FDA for this indication. The Phase 3 trial has been completed.
Metyrapone has been studied in a completed Phase 3 trial, NCT02297945, titled Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome. The trial enrolled 50 patients across Belgium, Germany, Hungary, Italy, Poland, Romania, Spain, and Turkey, and was an uncontrolled study.